224 related articles for article (PubMed ID: 26558731)
61. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
62. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
Hoffmann U; Lu MT; Olalere D; Adami EC; Osborne MT; Ivanov A; Aluru JS; Lee S; Arifovic N; Overton ET; Fichtenbaum CJ; Aberg JA; Alston-Smith B; Klingman KL; Waclawiw M; Burdo TH; Williams KC; Zanni MV; Desvigne-Nickens P; Cooper-Arnold K; Fitch KV; Ribaudo H; Douglas PS; Grinspoon SK;
Am Heart J; 2019 Jun; 212():1-12. PubMed ID: 30928823
[TBL] [Abstract][Full Text] [Related]
63. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
64. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Schmermund A; Achenbach S; Budde T; Buziashvili Y; Förster A; Friedrich G; Henein M; Kerkhoff G; Knollmann F; Kukharchuk V; Lahiri A; Leischik R; Moshage W; Schartl M; Siffert W; Steinhagen-Thiessen E; Sinitsyn V; Vogt A; Wiedeking B; Erbel R
Circulation; 2006 Jan; 113(3):427-37. PubMed ID: 16415377
[TBL] [Abstract][Full Text] [Related]
65. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.
Tani S; Watanabe I; Anazawa T; Kawamata H; Tachibana E; Furukawa K; Sato Y; Nagao K; Kanmatsuse K; Kushiro T;
Am J Cardiol; 2005 Oct; 96(8):1089-94. PubMed ID: 16214443
[TBL] [Abstract][Full Text] [Related]
66. Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events.
Singh P; Goncalves I; Tengryd C; Nitulescu M; Persson AF; To F; Bengtsson E; Volkov P; Orho-Melander M; Nilsson J; Edsfeldt A
Cardiovasc Diabetol; 2020 Dec; 19(1):214. PubMed ID: 33317535
[TBL] [Abstract][Full Text] [Related]
67. Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease.
Granér M; Kahri J; Nakano T; Sarna SJ; Nieminen MS; Syvänne M; Taskinen MR
Eur J Clin Invest; 2006 Nov; 36(11):764-70. PubMed ID: 17032343
[TBL] [Abstract][Full Text] [Related]
68. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
[TBL] [Abstract][Full Text] [Related]
69. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients.
Tawakol A; Lo J; Zanni MV; Marmarelis E; Ihenachor EJ; MacNabb M; Wai B; Hoffmann U; Abbara S; Grinspoon S
J Acquir Immune Defic Syndr; 2014 Jun; 66(2):164-71. PubMed ID: 24828267
[TBL] [Abstract][Full Text] [Related]
70. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
[TBL] [Abstract][Full Text] [Related]
71. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Qunibi W; Moustafa M; Muenz LR; He DY; Kessler PD; Diaz-Buxo JA; Budoff M;
Am J Kidney Dis; 2008 Jun; 51(6):952-65. PubMed ID: 18423809
[TBL] [Abstract][Full Text] [Related]
72. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
73. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score.
Che J; Li G; Wang W; Li Q; Liu H; Chen K; Liu T
Cardiol J; 2011; 18(4):364-70. PubMed ID: 21769816
[TBL] [Abstract][Full Text] [Related]
74. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease.
Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
Int J Cardiol; 2006 Nov; 113(2):167-73. PubMed ID: 16338010
[TBL] [Abstract][Full Text] [Related]
75. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
[TBL] [Abstract][Full Text] [Related]
76. Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease.
Sorokin AV; Hong CG; Aponte AM; Florida EM; Tang J; Patel N; Baranova IN; Li H; Parel PM; Chen V; Wilson SR; Ongstad EL; Collén A; Playford MP; Eggerman TL; Chen MY; Kotani K; Bocharov AV; Remaley AT
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37698922
[TBL] [Abstract][Full Text] [Related]
77. Association between circulating oxidized OxLDL/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes.
Xu L; Yan X; Tang Z; Feng B
Diabetes Res Clin Pract; 2022 Sep; 191():110040. PubMed ID: 35985428
[TBL] [Abstract][Full Text] [Related]
78. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV.
Looby SE; Fitch KV; Srinivasa S; Lo J; Rafferty D; Martin A; Currier JC; Grinspoon S; Zanni MV
AIDS; 2016 Jan; 30(3):383-93. PubMed ID: 26696388
[TBL] [Abstract][Full Text] [Related]
79. Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial.
Bays HE; Evans JL; Maki KC; Evans M; Maquet V; Cooper R; Anderson JW
Eur J Clin Nutr; 2013 Jan; 67(1):2-7. PubMed ID: 22948945
[TBL] [Abstract][Full Text] [Related]
80. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.
deFilippi C; Christenson R; Joyce J; Park EA; Wu A; Fitch KV; Looby SE; Lu MT; Hoffmann U; Grinspoon SK; Lo J
J Acquir Immune Defic Syndr; 2018 May; 78(1):105-110. PubMed ID: 29419569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
